Measurement of the upper limit of vulnerability during defibrillator implantation can substitute defibrillation threshold measurement

International Journal of Artificial Organs

Volumn 21, Issue 3, 1998, Pages 151-160

  Bessho, R ^a   Tanaka, S ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Antiarrhythmic drugs; Defibrillation threshold; Implantable cardioverter defibrillator; Life threatening ventricular arrhythmia; Myocardial injury; Upper limit of vulnerability

Indexed keywords

ELECTROCARDIOGRAPHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATORS; KETONES; PATIENT TREATMENT;

ANTIARRHYTHMIC DRUG; DEFIBRILLATION THRESHOLDS; IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; IMPLANTABLE CARDIOVERTERS-DEFIBRILLATORS; LIFE-THREATENING VENTRICULAR ARRHYTHMIA; MEASUREMENTS OF; MYOCARDIAL INJURY; UPPER LIMIT OF VULNERABILITY; UPPER LIMITS; VENTRICULAR ARRHYTHMIAS;

DEFIBRILLATORS;

AMIODARONE; CREATINE KINASE MB; DISOPYRAMIDE; MEXILETINE;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL ARTICLE; DEFIBRILLATION; DEFIBRILLATOR; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HUMAN; HUMAN TISSUE; IMPLANTATION; MALE; MEASUREMENT; RISK ASSESSMENT;

EID: 0031864691     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889802100306     Document Type: Article

References (39)

1. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980; 303: 322-4.
2. Bardy GH, Hofer B, Johnson G, et al. Implantable transvenous cardioverter-defibrillators. Circulation 1993; 87: 1152-68.
3. Lawton JS, Ellenbogen KA, Wood MA, et al. Clinical experience with nonthoracotomy cardioverter defibrillators. Ann Thorac Surg 1995; 59: 1092-9.
4. Winkle RA, Stinson EB, Echt DS, Mead RH, Schmidt P. Practical aspects of automatic cardioverter/defibrillator implantation. Am Heart J 1984; 108: 1335-46.
5. Fujimura O, Jones D, L. Klein GJ. The defibrillation threshold: how many measurements are enough? Am Heart J 1989; 117: 977-9.
6. Singer I, Laken J, Edmonds HL Jr, et al. Is defibrillation testing safe? PACE 1991; 14: 1899-1904.
7. Singer I, Edmonds H Jr, Slater D, Austin E. Cerebral hypoperfusion is an important factor to consider when programming implantable defibrillators (abstract) PACE 1992; 15:563.
8. Keyl C, Tassani P, Kemkes B, et al. Hemodynamic changes due to intraoperative testing of the automatic implantable cardioverter defibrillator: Implications for anesthesia management. J Cardiovasc Anesh 1993; 17: 442-7
9. Frame R, Brodman R, Furman S, et al. Clinical evaluation of the safety of repetitive intraoperative defibrillation threshold testing. PACE 1992; 15: 870-7.
10. Park WM, Amirhamzeh MMR, Jia CX, et al. Systolic arterial pressure recovery after ventricular fibrillation/flutter in humans. PACE 1994; 17: 1100-6.
11. Nakano H, Shiikawa A, Hayashi K, Akimoto T, Koyanagi H. Hemodynamic changes due to defibrillation threshold testing during implantation of the implantable cardioveter defibrillator. Jpn J Cardiac Pacing Electrophysiol 1996; 12: 28-33.
12. Avitall B, Port S, Gal R, et al. Automatic implantable cardioverter/defibrillator discharges and acute myocardial injury. Circulation 1990; 81: 1482-7.
13. Dahl C, Ewy GA, Warner ED, Thomas ED, Myocardial necrosis from direct current countershock. Circulation 1974; 50: 956.
14. Di Cola VC, Freedman GS, Downing SE, Zaret BL. Myocardial uptake of technetium-99m stannous pyrophosphate following direct current transthoracic countershock. Circulation 1976; 54: 980-6.
15. Doherty PW, Mc Laughlin PR, Billingham M, Kernoff R, Goris ML, Harrison DC. Cardiac damage produced by direct current countershock applied to the heart. Am J Cardiol 1979; 43: 225-32.
16. Jones JL, Paull WK, Proskarr CC, Jones R, Lepeschkin E, Rush S. Ultrastructural changes produced in cultured myocardial cells by electric shock. Fed Proc 1975; 34: 391.
17. Chen PS, Shibata N, Dixon MS, Martin RO, Ideker RE. Comparison of the defibrillation threshold and the upper limit of ventricular vulnerability. Circulation 1986; 73:1022-8.
18. Chen PS, Shibata N, Dixon EG, et al. Activation during ventricular defibrillation in open-chest dogs. J Clin Invst 1986; 77: 810-23.
19. Chen PS, Feld GK, Mower MM, Peters BB. Effects of pacing rate and timing of defibrillation shock on the relation between the defibrillation threshold and the upper limit of vulnerability in open chest dogs. J Am Coll Cardiol 1991; 18: 1555-63.
20. Souza JJ, Malkin RA, Ideker RE. Comparison of upper limit of vulnerability and defibrillation probability of success curves using a nonthoracotomy lead system. Circulation 1995; 91: 1247-52.
21. Bacon ME, Vitullo RN, Kasell JH, et al. Upper limit of vulnerability and its relationship to defibrillation threshold, in humans, (abstract) PACE 1992; 15: 530.
22. Chen PS, Feld GK, Kriett JM, et al. Relation between upper limit of vulnerability and defibrillation threshold in humans, Circulation 1993; 88: 186-92.
23. Bessho R, Nitta T, Tanaka S, et al. Relationship between defibrillation threshold and upper limit of vulnerability in humans. Jpn J Cardiac Pacing Electrophysiol 1996; 12: 315-20.
24. Hwang C, Swerdlow CD, Kass RM, et al. Upper limit of vulnerability reliably predicts the defibrillation threshold in humans. Circulation 1994; 90: 2308-14.
25. Kavanagh KM, Harrison JH, Dixon EG, et al. Correlation of the probability of success curve for defibrillation threshold and for the upper limit of vulnerability, (abstract) PACE 1990; 13: 536.
26. McDaniel WC, Schuder JC. An up-down algorithm for estimation of the cardiac ventricular defibrillation threshold. Medical Instrumentation 1988; 22: 286-92.
27. Nissan S, Mower MM, Thomas A, Hauser R. Patient survival comparison in three generations of automatic implantable cardioverter defibrillator of 12 years, 25000 patients. PACE 1993; 16: 174-8.
28. Chapman PD, Vetter JW, Souza JJ, Wetherbee JN, Troup PJ. Comparison of monophasic with single and dual capacitor biphasic waveforms for nonthoracotomy canine internal defibrillation. J Am Coll Cardiol 1989; 14: 2242-5.
29. Walcott GP, Walcott KT, Knisley SB, Zhou X, Ideker RE. Mechanism of defibrillation for monophasic and biphasic waveforms. PACE 1994; 17: 478-98.
30. Tanaka S, Nitta T, Bessho R, Biphasic waveforms and defibrillation. Jpn J Cardiac Pacing Electrophysiol 1995; 11: 259-67.
31. Shibata N, Chen PS, Dixon EG, et al. Influence of shock strength and timing on induction of ventricular arrhythmias in dogs. Am J Physiol 1988; 255: H891-H901.
32. O'Neil PG, Boahene KA, Lawne GM, Harvill LF, Pacifico A. The automatic implantable cardioverter-defibrillator: effect of patch polarity on defibrillation threshold. J Am Coll Cardiol 1991; 17: 707-11.
33. Ehsani A, Ewy GA, Sobel BE. Effects of electrical countershock on serum creatine phosphokinase (CPK) isoenzyme activity. Am J Cardiol 1976; 37: 12-8.
34. Singer I, Hutchins GM, Mirowski M, et al. Pathologic findings related to the lead system and repeated defibrillations in patients with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1987; 10: 382-8.
35. Van Vleet JF. Cardiac damage produced by defibrillation. In: Tacker WA, Geddes LA, eds Electrical Defibrillation. Boca Raton Fla CRC Press Inc, 1980; 137-53.
36. Singer I, Slater D, Mower M. Implantable cardioverter-defibrillator. In: Singer I, Kupersmith J, eds. Clinical Manual of Electrophysiology. Baltimore MD: Williams & Wilkins, 1993; 332-60.
37. Singer I, Lang D. Defibrillation threshold: clinical utilitiy and therapeutic implications. PACE 1992; 15: 932-49.
38. Topham SL, Cha YM, Peters BB, Chen PS. Effects of lidocaine on relation between defibrillation threshold and upper limit of vulnerability in open-chest dogs. Circulation 1992; 85: 1146-51.
39. Lang DJ, Swanson DK. Safety margin for defibrillation. Presented at 2nd International Congress on Rate Adaptive Cardiac Pacing and Implantable Defibrillators, October 10-13, Munich, West Germany.